-
Bayer Schering Pharma AG, et al v. Teva Pharamceuticals USA, Inc. DC
- 1:10-cv-00299
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 04/13/2010
- Closed: 11/21/2011
- Latest Docket Entry: 11/21/2011
- PACER
3
Plaintiffs
2
Defendants
4
Accused
Products
1
Patent-in-Suit
588
Days in
Litigation
-
Bayer Schering Pharma AG, et al v. Teva Pharamceuticals USA, Inc. DC
- 1:10-cv-00299
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 04/13/2010
- Closed: 11/21/2011
- Latest Docket Entry: 11/21/2011
- PACER
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A compound of the formula:</claim-text> <chemistry id="CHEM-US-00413" num="00413"><img id="EMI-C00413" he="57.40mm" wi="39.96mm" file="US07696206-20100413-C00413.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry> or a salt, a
view more
|
Enforceable and Valid
Entry 10 |
| 2 |
The compound according to claim 1 having the chemical name 2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one hydrochloride.
|
Enforceable and Valid
Entry 10 |
| 3 |
The compound according to claim 1 having the chemical name 2-[2-ethoxy-5-(4-ethyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one hydrochloride trihydrate.
|
Enforceable and Valid
Entry 10 |
| 4 |
A pharmaceutical composition comprising a compound according to claim 1 and a pharmacologically acceptable formulating agent.
|
Enforceable and Valid
Entry 10 |
| 5 |
A method of treating erectile dysfunction comprising administering to a mammal an effective amount of a compound according to claim 1.
|
Enforceable and Valid
Entry 10 |
| 6 |
The method of treating erectile dysfunction according to claim 5 wherein the mammal is a human.
|
Enforceable and Valid
Entry 10 |
